New, extended hairpin form of the TAR-2 RNA domain points to the structural polymorphism at the 5′ end of the HIV-2 leader RNA

Nucleic Acids Research

Volumn 34, Issue 10, 2006, Pages 2984-2997

  Pachulska Wieczorek, Katarzyna ^a   Purzycka, Katarzyna J ^a   Adamiak, Ryszard W ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

LEAD; MAGNESIUM; MUTANT PROTEIN; TRANSACTIVATING RESPONSIVE REGION 2 RNA; UNCLASSIFIED DRUG; VIRUS RNA; ARGININAMIDE; ARGININE; DIETHYL PYROCARBONATE; DRUG DERIVATIVE; RIBONUCLEASE; TRANSACTIVATOR PROTEIN;

5' UNTRANSLATED REGION; ARTICLE; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; ENZYMATIC DEGRADATION; GENETIC ENGINEERING; GENETIC POLYMORPHISM; HUMAN IMMUNODEFICIENCY VIRUS 2; IN VITRO STUDY; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PREDICTION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; RNA CLEAVAGE; RNA CONFORMATION; RNA STABILITY; RNA STRUCTURE; TERMINAL SEQUENCE; TRANSACTIVATION; CHEMISTRY; CONFORMATION; GEL MOBILITY SHIFT ASSAY; GENETICS; LONG TERMINAL REPEAT; METABOLISM; MOLECULAR GENETICS; NUCLEOTIDE SEQUENCE;

HUMAN IMMUNODEFICIENCY VIRUS 2;

5' UNTRANSLATED REGIONS; ARGININE; BASE SEQUENCE; BINDING SITES; DIETHYL PYROCARBONATE; ELECTROPHORESIS, POLYACRYLAMIDE GEL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; GENE PRODUCTS, TAT; HIV LONG TERMINAL REPEAT; HIV-2; LEAD; MAGNESIUM; MOLECULAR SEQUENCE DATA; NUCLEIC ACID CONFORMATION; RIBONUCLEASES; RNA, VIRAL;

EID: 33745157219     PISSN: 03051048     EISSN: 13624962     Source Type: Journal    
DOI: 10.1093/nar/gkl373     Document Type: Article

References (46)

1. Rabson, A.B. and Graves, B.J. (1997) Synthesis and processing of viral RNA. In Coffin, J.M., Hughes, S.H. and Varmus, H.E. (eds), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 205-262.
2. Arya, S.K. and Gallo, R.C. (1988) Human immunodeficiency virus type 2 long terminal repeat: Analysis of regulatory elements. Proc. Natl Acad. Sci. USA, 85, 9753-9757.
3. Berkhout, B. and Schoneveld, I. (1993) Secondary structure of the HIV-2 leader RNA comprising the tRNA-primer binding site. Nucleic Acids Res., 21, 1171-1178.
4. Dirac, A.M., Huthoff, H., Kjems., J. and Berkhout, B. (2002) Regulated HIV-2 RNA dimerization by means of alternative RNA conformations. Nucleic Acids Res., 30, 2647-2655.
5. Berkhout, B. and Jeang, K.T. (1989) Trans activation of human immunodeficiency virus type 1 is sequence specific for both the. single-stranded bulge and loop of the trans-acting-responsive hairpin: A quantitative analysis. J. Virol., 63, 5501-5504.
6. Rhim, H. and Rice, A.P. (1993) TAR RNA binding properties and relative transactivation activities of human immunodeficiency virus type 1 and 2 Tat proteins. J. Virol., 67, 1110-1121.
7. Berkhout, B. and Jeang, K.T. (1992) Functional roles for the TATA promoter and enhancers in basal and Tat-induced expression of the human immunodeficiency virus type 1 long terminal repeat. J. Virol., 66, 139-149.
8. Jones, K.A. and Peterlin, M. (1994) Control of RNA initiation and elongation at the HIV-1 promoter. Annu. Rev. Biochem., 63, 717-743.
9. Garcia-Martinez, L., Ivanov, D. and Gaynor, R. (1997) Association of Tat with purified HIV-1 and HIV-2 transcription preinitiation complexes. J. Biol. Chem., 272, 6951-6958.
10. Jones, K.A. (1997) Taking a new TAK on Tat transactivation. Genes Dev., 11, 2593-2599.
11. Wei, P., Garber, M.E., Fang, S., Fischer, W.H. and Jones, K.A. (1998) A novel CDK9-associated C-type cyclin interacts directly with HIV-1 Tat and mediates its high-affinity, loop-specific binding to TAR RNA. Cell, 92, 451-462.
12. Bieniasz, P.D., Grdina, T.A., Bogerd, H.P. and Cullen, B.R. (1999) Analysis of the effect of natural sequence variation in Tat and in cyclin T on the formation and RNA binding properties of Tat-cyclin T complexes. J. Virol., 73, 5777-57.
13. Richter, S., Cao, H. and Rana, T.M. (2002) Specific HIV-1 TAR RNA loop sequence and functional groups are required for human cyclin T1-Tat-TAR ternary complex formation. Biochemistry, 41, 6391-6397.
14. Reeves, J.D. and Doms, R.W. (2002) Human immunodeficiency virus type 2. J. Gen. Virol., 83, 1253-1265.
15. Froeyen, M. and Herdewijn, P. (2002) RNA as a target for drug design, the example of Tat-TAR interaction. Curr. Top. Med. Chem., 2, 1123-1145.
16. Hamy, F., Felder, E.R., Heizmann, G., Lazdins, J., Aboul-ela, F., Varani, G., Karn, J. and Klimkait, T. (1997) An inhibitor of the Tat/TAR RNA interaction that effectively suppresses HIV-1 replication. Proc. Natl Acad. Sci. USA, 94, 3548-3553.
17. Turner, J.J, Ivanova, G.D., Verbeure, B., Williams, D., Arzumanov, A.A., Abes, S., Lebleu, B. and Gait, M.J., (2005) Cell-penetrating peptide conjugates of peptide nucleic acids (PNA) as inhibitors of HIV-1 Tat-dependent trans-activation in cells. Nucleic Acids Res., 33, 6837-6849.
18. Aboul-ela, F., Karn, J. and Varani, G. (1996) Structure of HIV-1 TAR RNA in the absence of ligands reveals a novel conformation of the trinucleotide bulge. Nucleic Acids Res., 24, 3974-3981.
19. Kulinski, T., Olejniczak, M., Huthoff, H., Bielecki, L., Pachulska-Wieczorek, K., Das, A.T., Berkhout, B. and Adamiak, R.W. (2003) The apical loop of the HIV-1 TAR RNA hairpin is stabilized by a cross-loop base pair. J. Biol. Chem., 278, 38892-38901.
20. Puglisi, J.D., Tan, R., Calnan, B.J., Frankel, A.D. and Williamson, J.R. (1992) Conformation of the TAR RNA-arginine complex by NMR spectroscopy. Science, 257, 76-80.
21. Aboul-ela, F., Karn, J. and Varani, G. (1995) The structure of the human immunodeficiency virus type-1 TAR RNA reveals principles of RNA recognition by Tat protein. J. Mol. Biol., 253, 313-332.
22. 19F REDOR NMR. Nucleic Acids Res., 33, 3447-3454.
23. Emerman, M., Guyader, M., Montagnier, L., Baltimore, D. and Muesing, M.A. (1987) The specificity of the human immunodeficiency virus type 2 transactivator is different from that of human immunodeficiency virus type 1. EMBO J., 6, 3755-3760.
24. Selby, M.J., Bain, E.S., Luciw, P.A. and Peterlin, B.M. (1989) Structure, sequence, and position of the stem-loop in tar determine transcriptional elongation by tat through the HIV-1 long terminal repeat. Genes Dev., 3, 547-558.
25. Fenrick, R., Malim, M.H., Hauber, J., Le, S.Y., Maizel, J. and Cullen, B.R. (1989) Functional analysis of the Tat trans activator of human immunodeficiency virus type 2. J. Virol., 63, 5006-5012.
26. Berkhout, B. (1992) Structural features in TAR RNA of human and simian immunodeficiency viruses: A phylogenetic analysis. Nucleic Acids Res., 20, 27-31.
27. Rhim, H. and Rice, A.P. (1994) Functional significance of the dinucleotide bulge in stem-loop1 and stem-loop2 of HIV-2 TAR RNA. Virology, 202, 202-211.
28. Brodsky, A.S. and Williamson, J.R. (1997) Solution structure of the HIV-2 TAR-argininamide complex. J. Mol. Biol., 267, 624-639.
29. Brodsky, A.S., Erlacher, H.A. and Williamson, Jr. (1998) NMR evidence for a base triple in the HIV-2 TAR C-G.C+ mutant-argininamide complex. Nucleic Acids Res., 26, 1991-1995.
30. Berkhout, B., Gatignol, A., Silver, J. and Jeang, K.T. (1990) Efficient trans-activation by the HIV-2 Tat protein requires a duplicated TAR RNA structure. Nucleic Acids Res., 18, 1839-1846.
31. Garcia-Martinez, L.F., Mavankal, G., Peters, P., Wu-Baer, F. and Gaynor, R.B. (1995) Tat functions to stimulate the elongation properties of transcription complexes paused by the duplicated TAR RNA element of human immunodeficiency virus 2. J. Mol. Biol., 254, 350-363.
32. Oude Essink, B.B., Das, A.T. and Berkhout, B. (1996) HIV-1 reverse transcriptase discriminates against non-self tRNA primers. J. Mol. Biol., 264, 243-254.
33. Olejniczak, M., Gdaniec, Z., Fischer, A., Grabarkiewicz, T, Bielecki, L. and Adamiak, R.W. (2002) The bulge region of HIV-1 TAR RNA binds metal ions in solution. Nucleic Acids Res., 30, 4241-4249.
34. 2 by two-dimensional NMR and simulated annealing. Biochemistry, 35, 14077-14089.
35. Mathews, D.H., Sabina, J., Zucker, M. and Turner, D.H. (1999) Expanded sequence dependence of thermodynamic parameters improves prediction of RNA secondary structure. J. Mol. Biol., 288, 911-940.
36. Zucker, M. (2003) Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res., 31, 3406-3415.
37. Peattie, D.A. and Gilbert, W. (1980) Chemical probes for higher-order structure in RNA. Proc. Natl Acad. Sci. USA, 77, 4679-4682.
38. Rhim, H., Echetebu, C.O., Herrmann, C.H. and Rice, A.P. (1994) Wild-type and mutant HIV-1 and HIV-2 Tat proteins expressed in Escherichia coli as fusions with glutathione S-transferase. J. Acquir. Immune Defic. Syndr., 7, 1116-1121.
39. Dirac, A.M., Huthoff, H., Kjems, J. and Berkhout, B. (2001) The dimer initiation site hairpin mediates dimerization of the human immunodeficiency virus, type 2 RNA genome. J. Biol. Chem., 276, 32345-32352.
40. Sarkar, G., Yoon, H.S. and Sominer, S.S. (1992) Screening for mutations by RNA single-strand conformation polymorphism (rSSCP): Comparison with DNA-SSCP. Nucleic Acids Res., 20, 871-878.
41. Mandiyan, V. and Boublik, M. (1990) Structural analysis of the 5′ domain of the HeLa 185 ribosomal RNA by chemical and enzymatic probing. Nucleic Acids Res., 18, 7055-7062.
42. Krzyzosiak, W.J., Marciniec, T., Wiewiorowski, M., Romby, P., Ebel, J.P. and Giege, R. (1988) Characterization of the lead(II)-induced cleavages in tRNAs in solution and effect of the Y-base removal in yeast tRNA Phe. Biochemistry, 15, 5771-5777.
43. Ciesiolka, J., Wrzesinski, J., Gornicki, P., Podkowinski, J. and Krzyzosiak, W.J. (1989) Analysis of magnesium, europium and lead binding sites in methionine initiator and elongator tRNAs by specific metal-ion-induced cleavages. Eur. J. Biochem., 186, 71-77.
44. Ciesiolka, J., Michalowski, D., Wrzesinski, J., Krajewski, J. and Krzyzosiak, W.J. (1998) Patterns of cleavages induced by lead ions in defined RNA secondary structure motifs. J. Mol. Biol., 275, 211-220.
45. Tao, J. and Frankel, A.D. (1992) Specific binding of arginine to TAR RNA. Proc. Natl Acad. Sci. USA, 89, 2723-2726.
46. Rhim, H. and Rice, A.P. (1997) RNAs selected in vitro by the IHV-2 Tat Protein. J. Biomed. Sci., 4, 28-34.